Skip to search formSkip to main contentSkip to account menu

t(4;14)

A chromosomal translocation that involves the chromosomes 4 and 14.
National Institutes of Health

Related topics

Related topics

2 relations
Chromosomes, Human, Pair 14Chromosomes, Human, Pair 4

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk…
8006Background: In 2 randomized phase 3 trials of RRMM patients (pts), DRd (POLLUX) or DVd (CASTOR) significantly improved PFS… 
2017
2017
Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study
BackgroundThe EMN02/HO95 trial is the largest multicenter, randomized, phase 3 study conducted in the novel agent era and aimed… 
2009
2009
FGFR3 is expressed and is important for survival in INA‐6, a human myeloma cell line without a t(4;14)
Objectives:  Fibroblast growth factor receptor 3 (FGFR3) is a proto‐oncogene that is often dysregulated together with multiple… 
2009
2009
Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
Review
2008
Review
2008
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy
A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of… 
2008
2008
Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide
The chromosomal abnormalities of del(13), t(4;14), and del(17p) are associated with poor progression-free survival (PFS) and… 
2007
2007
Chromosomal Translocations t(4;14), t(11;14) and Proliferation Rate Stratify Patients With Mature Plasma Cell Myelomas Into Groups With Different Survival Probabilities—A Molecular Epidemiologic…
Plasma cell myelomas (PMs) exhibit clinical and molecular heterogeneity. To date, morphology and immunohistochemistry on bone… 
2007
2007
Detection and follow‐up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma
The t(4;14)(p16;q32) translocation, found in 15% of multiple myeloma (MM) cases, indicates a poor prognosis. Plasma cells (PC… 
Highly Cited
2004
Highly Cited
2004
A Global Expression-based Analysis of the Consequences of the t(4;14) Translocation in Myeloma
Purpose: Our purpose in this report was to define genes and pathways dysregulated as a consequence of the t(4;14) in myeloma, and… 
2003
2003
Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism
Using FISH-based techniques, rearrangements of the immunoglobulin heavy-chain (IgH) locus at 14q32 have been found in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)